The family of voltage-gated calcium channels serves as the key transducers of cell surface membrane potential changes into local intracellular calcium transients that initiate many different physiological events. There are 10 members of the voltage-gated calcium channel family that have been characterized in mammals, and they serve distinct roles in cellular signal transduction. This article presents the molecular relationships and physiological functions of these calcium channel proteins and provides comprehensive information on their molecular, genetic, physiological, and pharmacological properties.
Introduction
Voltage-gated calcium channels mediate calcium influx in response to membrane depolarization and regulate intracellular processes such as contraction, secretion, neurotransmission, and gene expression in many different cell types. Their activity is essential to couple electrical signals in the cell surface to physiological events in cells. They are members of a gene superfamily of transmembrane ion channel proteins that includes voltage-gated potassium and sodium channels (Yu and Catterall, 2004) . This compendium presents an introduction to their biochemical, molecular, and genetic properties, their physiological roles, and their pharmacological significance. Table 1 and the summary tables that follow the text of this article give comprehensive information on each member of the calcium channel family.
Calcium Channel Subunits
The calcium channels that have been characterized biochemically are complex proteins composed of four or five distinct subunits that are encoded by multiple genes ( Fig. 1; Catterall, 2000) . The ␣ 1 subunit of 190 to 250 kDa is the largest subunit, and it incorporates the conduction pore, the voltage sensor and gating apparatus, and most of the known sites of channel regulation by second messengers, drugs, and toxins. Like the ␣ sub-units of sodium channels, the ␣ 1 subunit of voltagegated calcium channels is organized in four homologous domains (I-IV), with six transmembrane segments (S1-S6) in each. The S4 segment serves as the voltage sensor. The pore loop between transmembrane segments S5 and S6 in each domain determines ion conductance and selectivity, and changes of only three amino acids in the pore loops in domains I, III, and IV will convert a sodium channel to calcium selectivity. An intracellular ␤ subunit and a transmembrane, disulfide-linked ␣ 2 ␦ subunit complex are components of most types of calcium channels. A ␥ subunit has also been found in skeletal muscle calcium channels, and related subunits are expressed in heart and brain. Although these auxiliary subunits modulate the properties of the channel complex, the pharmacological and electrophysiological diversity of calcium channels arises primarily from the existence of multiple ␣ 1 subunits (Hofmann et al., 1994).
Calcium Currents
Calcium currents recorded in different cell types have diverse physiological and pharmacological properties, and an alphabetical nomenclature has evolved for the distinct classes of calcium currents . L-type calcium currents typically require a strong depolarization for activation, are long-lasting, and are blocked by the organic L-type calcium channel antagonists, including dihydropyridines, phenylalkylamines, and benzothiazepines. They are the main calcium currents recorded in muscle and endocrine cells, where they initiate contraction and secretion. L-type currents activating at lower voltages also exist predominantly in neurons and cardiac pacemaker cells. N-type, P/Q-type, and R-type calcium currents also require strong depolarization for activation. They are relatively unaffected by L-type calcium channel antagonist drugs but are blocked by specific polypeptide toxins from snail and spider venoms. They are expressed primarily in neurons, where they initiate neurotransmission at most fast synapses and mediate calcium entry into cell bodies and dendrites. T-type calcium currents are activated by weak depolarization and are transient. They are resistant to both organic antagonists and to the snake and spider toxins used to define the N-and P/Q-type calcium currents. They are expressed in a wide variety of cell types, where they are involved in shaping the action potential and controlling patterns of repetitive firing.
Calcium Channel Genes
Mammalian ␣ 1 subunits are encoded by at least 10 distinct genes. Historically, various names have been given to the corresponding gene products, giving rise to FIG. 1. Subunit structure of Ca V 1 channels. The subunit composition and structure of calcium channels purified from skeletal muscle are illustrated. The model is updated from the original description of the subunit structure of skeletal muscle calcium channels. This model fits available biochemical and molecular biological results for other Ca V 1 channels and for Ca V 2 channels. Predicted ␣ helices are depicted as cylinders. The lengths of lines correspond approximately to the lengths of the polypeptide segments represented. distinct and sometimes confusing nomenclatures. In 1994, a unified but arbitrary nomenclature was adopted in which ␣ 1 subunits were referred to as ␣ 1S for the original skeletal muscle isoform and ␣ 1A through ␣ 1E for those discovered subsequently (Birnbaumer et al., 1994) . In 2000, a rational nomenclature was adopted based on the well defined potassium channel nomenclature (Chandy and Gutman, 1993) . Calcium channels were named using the chemical symbol of the principal permeating ion (Ca) with the principal physiological regulator (voltage) indicated as a subscript (Ca V ). The numerical identifier corresponds to the Ca V channel ␣ 1 subunit gene subfamily (1 to 3 at present) and the order of discovery of the ␣ 1 subunit within that subfamily (1 through n). According to this nomenclature, the Ca V 1 subfamily (Ca V 1. The complete amino acid sequences of these ␣ 1 subunits are more than 70% identical within a subfamily but less than 40% identical among the three subfamilies. These family relationships are illustrated for the more conserved transmembrane and pore domains in Fig. 2 . The division of calcium channels into these three families is phylogenetically ancient, as representatives of each are found in the Caenorhabditis elegans genome. Consequently, the genes for the different ␣ 1 subunits have become widely dispersed in the genome, and even the most closely related members of the family are not clustered on single chromosomes in mammals.
Calcium Channel Molecular Pharmacology
The pharmacology of the three subfamilies of calcium channels is quite distinct. The Ca V 1 channels are the molecular targets of the organic calcium channel blockers used widely in the therapy of cardiovascular diseases. These drugs are thought to act at three separate, but allosterically coupled, receptor sites (Table 1; reviewed in . Phenylalkylamines are intracellular pore blockers, which are thought to enter the pore from the cytoplasmic side of the channel and block it. Their receptor site is formed by amino acid residues in the S6 segments in domains III and IV, in close analogy to the local anesthetic receptor site on sodium channels Hofmann et al., 1999; . Dihydropyridines can be channel activators or inhibitors and therefore are thought to act allosterically to shift the channel toward the open or closed state rather than by occluding the pore. Their receptor site includes amino acid residues in the S6 segments of domains III and IV and the S5 segment of domain III. The dihydropyridine receptor site is closely apposed to the phenylalkylamine receptor site and shares some common amino acid residues. Diltiazem and related benzothiazepines are thought to bind to a third receptor site, but the amino acid residues that are required for their binding overlap extensively with those required for phenylalkylamine binding.
The Ca V 2 subfamily of calcium channels is relatively insensitive to dihydropyridine calcium channel blockers, but these calcium channels are specifically blocked with high affinity by peptide toxins from spiders and marine snails (Miljanich and Ramachandran, 1995). The Ca V 2.1 channels are blocked specifically by -agatoxin IVA from funnel web spider venom. The Ca V 2.2 channels are blocked specifically by -conotoxin GVIA and related cone snail toxins. The Ca V 2.3 channels are blocked specifically by the synthetic peptide toxin SNX-482 derived from tarantula venom. These peptide toxins are potent blockers of synaptic transmission because of their specific effects on the Ca V 2 family of calcium channels.
The Ca V 3 subfamily of calcium channels are insensitive to both the dihydropyridines that block Ca V 1 channels and the spider and cone snail toxins that block the Ca V 2 channels, and there are no widely useful pharmacological agents that block T-type calcium currents (Perez-Reyes, 2003). The organic calcium channel blocker mibefradil is somewhat selective for T-type versus L-type calcium currents (3-to 5-fold). The peptide kurtoxin inhibits the activation gating of Ca V 3.1 and Ca V 3.2 channels. Development of more specific and high-affinity blockers of the Ca V 3 family of calcium channels would be useful for therapy and a more detailed analysis of the physiological roles of these channels. Tables 2 through 11 summarize the major molecular, physiological, and pharmacological properties for each of the 10 calcium channels that have been functionally expressed. Quantitative data are included for FIG. 2. Sequence similarity of voltage-gated calcium channel ␣ 1 subunits. Phylogenetic representation of the primary sequences of the calcium channels. Only the membrane-spanning segments and pore loops (ϳ350 amino acids) are compared. First, all sequence pairs were compared, which clearly defines three subfamilies with intrafamily sequence identities above 80% (Ca V 1, Ca V 2, and Ca V 3). Then a consensus sequence was defined for each subfamily, and these three sequences were compared to one another, with intersubfamily sequence identities of ϳ52% (Ca V 1 vs. Ca V 2) and 28% (Ca V 3 vs. Ca V 1 or Ca V 2). NOMENCLATURE AND RELATIONSHIPS OF VOLTAGE-GATED CALCIUM CHANNELS voltage dependence of activation and inactivation, single-channel conductance, and binding of drugs and neurotoxins, focusing on those agents that are widely used and diagnostic of channel identity and function. Glossmann The gene for Ca v 1.1 was first isolated and characterized in rabbit (1873aa, M23919, X05921); several groups reported three-dimensional structures of the purified skeletal muscle calcium channel complex determined using electron cryomicroscopy and single-particle averaging 14 Tissue-specific splice variants exist-in addition to cardiac channels, smooth muscle and brain channels have been cloned 7, 21, 22 ; the gene for Ca v 1.2 was first isolated and characterized in rabbit heart (2171aa, P15381, X15539) ; in functional experiments, however, Ca v 1.2 channels show higher DHP sensitivity-this discrepancy is explained by the slower inactivation of Ca v 1.3 decreasing the availability of inactivated channels for state-dependent DHP block Channel distribution Sensory cells (photoreceptors, cochlear hair cells 1,2 ), endocrine cells (including pancreatic ␤-cells, pituitary, adrenal chromaffin cells, pinealocytes), 7-9 low density in heart (atrial muscle, sinoatrial and atrioventricular node) 1,7,10 and vascular smooth muscle 7 ; neurones 6 ; subcellular localization: on neurones preferentially located on proximal dendrites and cell bodies 6 
Physiological functions
Neurotransmitter release in sensory cells, control of cardiac rhythm and atrioventricular node conductance at rest, 1,10,12 mood behavior, 12 hormone secretion Mutations and pathophysiology Deafness, sinoatrial and atrioventricular node dysfunction, 1,10,12 no convincing evidence for contribution to pancreatic ␤-cell L-type currents and insulin secretion in mouse models 1, 12, 13 
Pharmacological significance
Hypothetical drug targets for modulators of heart rate, 1 antidepressant drugs 10 
and drugs for hearing disorders 1 Comments
Tissue-specific and developmental (exon 1b) splice variants exist-in addition to brain, pancreatic ␤-cell and cochlear variants have been cloned; it is likely that Ca v 1.3 channels form most of the so-called Јlow-voltage-activatedЈ L-type currents found in the brain and sinoatrial node, although some splice variants of Ca v 1.2 can also activate at more negative potentials Neurotransmitter release in central neurons and neuromuscular junction; excitation-secretion coupling in pancreatic ␤-cells Mutations and pathophysiology Missense mutations in IS4-IS5, IIS4-IIS6, IIIS4-IIIS6, and IVS4-IVS6 cause FHM 27 ; a common feature among FHM mutations is an apparent gain-of-function phenotype as a result of a shift in V 50act to more hyperpolarized potentials (an increased probability of opening at the single channel level) 28, 29 ; other effects include a decrease in maximal current density at the whole-cell level and alterations of synaptic transmission [28] [29] [30] [31] ; point mutations in IIS1, IIS6-IIIS2, IIIS5-IIIS6, and IVS1-IVS5 cause episodic ataxia type-2, a polyglutamine expansion in the carboxyl region causes spinocerebellar ataxia type-6, and mutation of IS5-IS6 and IVS6 causes episodic and progressive ataxia [10] [11] [12] 27 Pharmacological significance Peptide toxins that selectively inhibit Ca V 2.1 channel block a significant portion of neurotransmission in the mammalian CNS 13 ; block of Ca V 2.1 channels inhibits the late-phase formalin response and inflammatory pain but has no significant effect on mechanical allodynia or thermal hyperalgesia [14] [15] [16] [17] ; mice lacking a functional Ca V 2.1 gene exhibit cerebellar atrophy, severe muscle spasms, and ataxia and usually die by 3 to 4 weeks postnatal 18, 19 
Comments
Rates of inactivation and V h are differentially affected by coexpression with ␤ 1b , ␤ 2a , ␤ 3 , or ␤ 4 subunits, as well as by alternative splicing of the ␣ 1A subunit; identified regions of alternative splicing include the domain I-II linker, domain II-III linker, IVS3-IVS4, and the carboxyl terminus 1,2,6,32-34 ; whole-cell currents with P-type kinetics seem to be conducted by the ␣ 1A-b splice variant coexpressed with any of the ␤ subunits or by the ␣ 1A-a splice variant coexpressed with the ␤ 2a subunit 6, 7, 20 ; whole-cell currents with Q-type kinetics seem to be encoded by ␣ 1A-a coexpressed with any of the ␤ 1b , ␤ 3 , or ␤ 4 subunits 6,20 ; whole-cell currents with Q-type pharmacology seem to be encoded by ␣ 1A splice variants containing Asp Pro residues in the domain IV S3-S4 linker, whereas whole-cell currents with P-type pharmacology seem to be conducted by ␣ 1A splice variants missing Asp Pro residues in IV S3-S4 linker 3, 6 ; alternative splicing also alters current density, current-voltage relations, calcium/calmodulin-dependent facilitation, sensitivity to mibefradil, and binding to intracellular synaptic proteins such as Mint1, CASK, syntaxin, and SNAP-25 26, 32, 36 4 
Channel distribution
Neurons (presynaptic terminals, dendrites, cell bodies) 9 
Physiological functions
Neurotransmitter release in central and sympathetic neurons 10 ; sympathetic regulation of the circulatory system 11, 35 ; activity and vigilance state control 36 ; sensation and transmission of pain (see "Pharmacological significance" and "Comments") Mutations and pathophysiology Differing reports exist: mice lacking a functional Ca V 2.2 gene exhibit a normal life span and no detectable behavioral modifications compared with wild type but possess an increase in basal mean atrial pressure and other functional alterations to the sympathetic nervous system 11 -however, in a different study, approximately 1/3 of the mice lacking a functional Ca V 2.2 gene did not survive to weaning, but surviving animals were normal except for a decrease in anxiety-related behavior and a suppression of inflammatory and neuropathic pain responses 12 ; no point mutations in the native Ca V 2.2. gene have been reported to date Pharmacological significance
In rats, intrathecal administration of -conotoxin GVIA or -conotoxin MVIIA shows strong effects on inflammatory pain, postsurgical pain, thermal hyperalgesia, and mechanical allodynia [13] [14] [15] ; in humans, intrathecal administration of SNX-111 (Ziconotide/Prialt, synthetic -conotoxin MVIIA) to patients unresponsive to intrathecal opiates significantly reduced pain scores and in a number of specific instances resulted in relief after many years of continuous pain 16 
Comments
In case studies, Ziconotide/Prialt has been examined for usefulness in the management of intractable spasticity following spinal cord injury in patients unresponsive to baclofen and morphine 17 ; side effects of intrathecal administration of Ziconotide/Prialt include nystagmus, sedation, confusion, auditory and visual hallucinations, severe agitation, and unruly behavior 18 ; intravenous administration of Ziconotide to humans results in significant orthostatic hypotension 19 ; identified regions of alternative splicing include the domain I-II linker, domain II-III linker, IIIS3-IIIS4, IVS3-IVS4, and the carboxyl terminus [1] [2] [3] [4] [37] [38] [39] ; splicing affects a number of channel properties, including current-voltage relations and kinetics, and is associated with cellspecific expression-in particular, expression of the e37a splice isoform in dorsal root ganglia correlates with a subset of nociceptive neurons [40] [41] [42] ; alternative splicing also alters interactions with intracellular synaptic proteins such as Mint1, CASK, syntaxin, and SNAP-25 [43] [44] [45] Ca v 2.3 has been variously reported to encode a novel type of calcium channel with properties shared between both low-and high-threshold calcium channels 1, 4 or a type of high-threshold channel resistant to DHPs, -agatoxin-IVA, and -conotoxin-GVIA and called R-type (for "residual") 7 The tarantula toxin SNX-482 blocks exogenously expressed Ca v 2.3 currents 8 but is only partially effective on native cerebellar R-type currents, 9 suggesting that Ca v 2.3 does not always conduct a significant portion of the R-type current as originally defined 7 ; identified regions of alternative splicing include the domain II-III linker and carboxyl terminus and have been shown to affect channel kinetics and Ca 2ϩ -dependent stimulation [1] [2] [3] 15, 16 19 and other thalamocortical dysrhythmias 20 
Splice variants that differ in their voltage dependence have been cloned 5 Ca v 3.2 is more sensitive than Ca v 3.1 to block by nickel (IC 50 ϭ 12 M) 5 and possibly phenytoin 6 and amiloride 2, 7 ; selective for Ca v 3.x relative to Ca v 1.x and Ca v 2.x: mibefradil, 8,9 U92032, 10 penfluridol and pimozide, 11 and amiloride 12 ; nonselective: nimodipine, 2 anesthetics 5 Radioligands None Channel distribution Kidney (human Northern 1 ), rat smooth muscle (RT-PCR 13 ), liver (human Northern 1 ), adrenal cortex (rat, bovine; in situ hybridization and RT-PCR 14 ), brain (especially in olfactory bulb, striatum, cerebral cortex, hippocampus, reticular thalamic nucleus; rat in situ hybridization 15 ), and heart (especially sinoatrial node; mouse in situ hybridization 16 ) Physiological functions
Smooth muscle contraction, 17 smooth muscle proliferation, 18 aldosterone secretion, 19 cortisol secretion 20 Mutations and pathophysiology Single nucleotide polymorphisms associated with childhood absence epilepsy patients in a Chinese population 21 
Pharmacological significance
May mediate effect of absence antiepileptic drugs such as ethosuximide 22 and other thalamocortical dysrhythmias 23 ; potential drug target in hypertension and angina pectoris 24 
Comments
Splice variation found in the linker connecting repeat 3 and 4 25 14 and other thalamocortical dysrhythmias 15 
Splice variants have been reported 16 
